The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reverse phase protein microarray for identification of IL6 receptor ligation-induced insulin receptor, PI3K/AKT, and JAK/STAT signaling pathways in the CARD11 mutated lymphoma cell line OCI-Ly3.
Greg Coffey
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Akiko Futamura
Employment or Leadership Position - Carna Biosciences
Shruti Shrivastav
Employment or Leadership Position - Portola Pharmaceuticals
Yoshinori Tanizawa
Employment or Leadership Position - Carna Biosciences
Takeomi Inoue
Employment or Leadership Position - Carna Biosciences
Naoko Iwata
Employment or Leadership Position - Carna Biosciences
Yasuyuki Kirii
Employment or Leadership Position - Carna Biosciences
Pamela Conley
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Anjali Pandey
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals